Database→Selank

Tier 3CognitiveMood / AntidepressantAnxietyPREMIUM

Selank

Selank (TP-7) -- Synthetic Tuftsin Analog, GABAergic Anxiolytic Heptapeptide

Approved in Russia and Ukraine since 2009 as a prescription intranasal medication (0.15% nasal drops) for generalized anxiety disorder (GAD) and neurasthenia. Trade name: Selanc. Not FDA-approved. Not EMA-approved. No IND filed in the United States. Not on WADA Prohibited List. Classified as a research compound outside Russia and Ukraine.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics, Russian Academy of Sciences, as a metabolically stabilized analog of tuftsin. It is approved in Russia since 2009 as an intranasal anxiolytic for GAD and neurasthenia. The pivotal clinical study (Zozulya et al., 2008, n=62) compared Selank to medazepam and found comparable anxiolytic efficacy with additional antiasthenic and psychostimulant effects. All human clinical data comes from Russian institutions; no GCP-compliant international trials exist.

🔒

Full Profile: Premium Members Only

The complete Selank profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use